The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis.

found that the proportion of patients with high PD‐L1 expression (≥50%) after progression during EGFR‐TKI treatment increased from 14% to 28%, and TMB also showed an increasing trend (3.3 → 4.1108 mutations/Mbp, p = 0.0508) through rebiopsy of patients, so that it enters into the immune‐supportive TME, which may provide basis for the subsequent ICIs treatment optimization. 52 Maynard et al. used single‐cell RNA sequencing to identify decreased T‐cell infiltration (46% vs. 3

also in 63,971 other papers

In all subset analyses, ICIs+Chemo and ICIs+Chemo+Antiangio showed PFS benefits compared with Chemo and ICIs, respectively, but the differences did not reach statistical significance (Supplement 14 in Appendix S1 ).

also in 111,027 other papers